Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meropenem + sargramostim + human albumin
- Development stage
- Unknown
- Lead developer
- Partner Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
Meropenem + sargramostim + human albumin is a combination therapeutic regimen investigated by the Institute of Liver and Biliary Sciences (ILBS) in India for the treatment of difficult-to-treat spontaneous bacterial peritonitis (SBP) in patients with decompensated cirrhosis. The regimen combines meropenem, a broad-spectrum carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), with sargramostim (granulocyte-macrophage colony-stimulating factor or GM-CSF), a cytokine that stimulates the production and activation of neutrophils and macrophages to overcome the immune dysfunction typically seen in advanced cirrhosis. Human albumin is included to provide oncotic support and reduce the incidence of renal impairment. Clinical trial results indicated that the addition of GM-CSF to the standard carbapenem and albumin therapy significantly improved response rates in patients with treatment-resistant SBP.
- Other names
- Carbepenem + GM-CSF + AlbuminMeropenem + GM-CSF + AlbuminGM-CSF + Carbapenem + Albumin
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on meropenem + sargramostim + human albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meropenem + sargramostim + human albumin.